Peter Riedell, MD, University of Chicago Medicine, Chicago, IL, analyses the findings from a study which focuses on patients with mantle cell lymphoma (MCL). Dr Riedell noted a high application of R-CHOP as induction therapy, however multiple data sets suggest that bendamustine-based therapy may be superior to R-CHOP based treatments. Dr Riedell also touches on the reduced utilization of autologous stem cell transplants in the community setting, indicating that this is an area where awareness is required. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.